<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02895945</url>
  </required_header>
  <id_info>
    <org_study_id>241502</org_study_id>
    <secondary_id>2015-005521-39</secondary_id>
    <nct_id>NCT02895945</nct_id>
  </id_info>
  <brief_title>BAX 802 in CHA With Inhibitors</brief_title>
  <acronym>CHAWI</acronym>
  <official_title>A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxalta Innovations GmbH, now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of BAX 802 in males with
      congenital hemophilia A (CHA) with inhibitors who are undergoing major or minor elective
      surgical, dental, or other invasive procedures.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Protocol amendment needed.
  </why_stopped>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Anticipated">April 16, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Hemostatic Efficacy Assessment score (GHEA)- composed of 3 individual ratings: Day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>GHEA=Sum of 1-3 ratings. Excellent: 7-9 (no category &lt;2) Good: 5-7 (no category &lt;1) Fair: 3-4 (no category &lt;1) None 0-2 (≥ category 0). a. Intra operative hemostatic efficacy (Excellent=3: Good=2: Fair=1: None =0). b. Hemostatic efficacy postoperative Day 1 (Excellent=3: Good=2: Fair=1: None =0). c. Overall perioperative hemostatic efficacy at discharge or within 24 to 72 hours after last perioperative treatment dose of BAX 802 (whichever is earlier) (Excellent=3: Good=2: Fair=1: None =0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Hemostatic Efficacy Assessment score (GHEA)- composed of 3 individual ratings: Day 1</measure>
    <time_frame>Day 1</time_frame>
    <description>GHEA=Sum of 1-3 ratings. Excellent: 7-9 (no category &lt;2) Good: 5-7 (no category &lt;1) Fair: 3-4 (no category &lt;1) None 0-2 (≥ category 0). a. Intra operative hemostatic efficacy (Excellent=3: Good=2: Fair=1: None =0). b. Hemostatic efficacy postoperative Day 1 (Excellent=3: Good=2: Fair=1: None =0). c. Overall perioperative hemostatic efficacy at discharge or within 24 to 72 hours after last perioperative treatment dose of BAX 802 (whichever is earlier) (Excellent=3: Good=2: Fair=1: None =0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global Hemostatic Efficacy Assessment score (GHEA)- composed of 3 individual ratings: At discharge or within 24 to 72 hours after last perioperative treatment dose of BAX 802 (whichever is earlier)</measure>
    <time_frame>At discharge or within 24 to 72 hours after last perioperative treatment dose of BAX 802 (whichever is earlier)</time_frame>
    <description>GHEA=Sum of 1-3 ratings. Excellent: 7-9 (no category &lt;2) Good: 5-7 (no category &lt;1) Fair: 3-4 (no category &lt;1) None 0-2 (≥ category 0). a. Intra operative hemostatic efficacy (Excellent=3: Good=2: Fair=1: None =0). b. Hemostatic efficacy postoperative Day 1 (Excellent=3: Good=2: Fair=1: None =0). c. Overall perioperative hemostatic efficacy at discharge or within 24 to 72 hours after last perioperative treatment dose of BAX 802 (whichever is earlier) (Excellent=3: Good=2: Fair=1: None =0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra- and post-operative blood loss compared to the estimated volume of expected average blood loss in a comparable healthy individual</measure>
    <time_frame>End of surgery; approximately 24 hours after surgery; and at discharge or 24 to 72 hours after the last perioperative treatment dose of BAX 802 (whichever is earlier)</time_frame>
    <description>Predicted preoperatively by the investigator/surgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra- and post-operative blood loss compared to the expected maximum blood loss in a comparable healthy individual</measure>
    <time_frame>End of surgery; approximately 24 hours after surgery; and at discharge or 24 to 72 hours after the last perioperative treatment dose of BAX 802 (whichever is earlier)</time_frame>
    <description>Predicted preoperatively by the investigator/surgeon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major surgeries with good or excellent hemostatic score</measure>
    <time_frame>Day 0 (day of surgery) thru Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Proportion of major surgeries with good or excellent hemostatic score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily weight-adjusted administration of BAX 802</measure>
    <time_frame>Day 0 (postoperative) thru Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Daily weight-adjusted administration of BAX 802 per participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total weight-adjusted administration of BAX 802</measure>
    <time_frame>Day 0 (postoperative) thru Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Total weight-adjusted administration of BAX 802 per participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of blood products transfused</measure>
    <time_frame>From initiation of the surgery until Day 14 or discharge (whichever is earlier)</time_frame>
    <description>Amount of blood products (e.g., whole blood, red blood cells, platelets, and plasma) transfused</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of, and changes to, the titer of inhibitory and binding antibodies to porcine factor VIII (pFVIII)</measure>
    <time_frame>&gt;14 days prior to Day 0 (surgery day); 7-14 days after last perioperative treatment dose of BAX 802; and day 42 after last perioperative treatment dose of BAX 802</time_frame>
    <description>Development of, and changes to, the titer of inhibitory and binding antibodies (IgG and IgM) to porcine factor VIII (pFVIII)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of, and changes to, the titer of inhibitory and binding antibodies to human factor VIII (hFVIII)</measure>
    <time_frame>&gt;14 days prior to Day 0 (surgery day); 7-14 days after last perioperative treatment dose of BAX 802; and day 42 after last perioperative treatment dose of BAX 802</time_frame>
    <description>Development of, and changes to, the titer of inhibitory and binding antibodies (IgG and IgM) to human factor VIII (hFVIII)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding antibodies to baby hamster kidney (BHK) proteins</measure>
    <time_frame>≤45 days prior to Day 0 (surgery day); 7-14 days after last perioperative treatment dose of BAX 802; and day 42 after last perioperative treatment dose of BAX 802</time_frame>
    <description>Development of binding antibodies to baby hamster kidney (BHK) proteins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombo-embolic events</measure>
    <time_frame>Day 0 (surgery day) through end of study visit (day 42 after discharge)</time_frame>
    <description>Occurrence of thrombo-embolic events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe allergic reactions</measure>
    <time_frame>Day 0 (surgery day) through end of study visit (day 42 after discharge)</time_frame>
    <description>Incidence of severe allergic reactions (eg, anaphylaxis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other investigational product (IP)-related adverse events (AEs)</measure>
    <time_frame>From Day 0 (day of surgery) through Day 42 post-surgery (End of Study Visit)</time_frame>
    <description>Incidence of other investigational product (IP)-related adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in vital signs</measure>
    <time_frame>Within 30 minutes pre, and 30 minutes post-dose</time_frame>
    <description>Incidence of clinically significant changes in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in routine laboratory parameters - hematology labs</measure>
    <time_frame>Screening visit (up to 45 days prior to day of surgery (Day 0)) through End of Study Visit (Day 42 post-surgery)</time_frame>
    <description>Incidence of clinically significant changes in routine laboratory parameters - hematology labs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in routine laboratory parameters - clinical chemistry</measure>
    <time_frame>Screening visit (up to 45 days prior to day of surgery (Day 0)) through End of Study Visit (Day 42 post-surgery)</time_frame>
    <description>Incidence of clinically significant changes in routine laboratory parameters - clinical chemistry</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>BAX802 in Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who are undergoing major or minor elective surgical, dental, or other invasive procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)</intervention_name>
    <description>In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.</description>
    <arm_group_label>BAX802 in Surgery</arm_group_label>
    <other_name>BAX 802</other_name>
    <other_name>BAX802</other_name>
    <other_name>recombinant porcine factor VIII</other_name>
    <other_name>Obizur</other_name>
    <other_name>rpFVIII</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Participant requires a major or minor elective surgical, dental or other invasive
             procedure

          2. Participant is male and ≥ 12 to ≤ 75 years old at the time of screening

          3. Participant has provided signed informed consent (and assent for adolescent
             participants, as applicable) in accordance with local regulatory requirements

          4. Participant has severe (factor VIII (FVIII) level &lt; 1%) or moderately severe (FVIII
             level ≤ 2%) congenital hemophilia A (CHA) with inhibitors to human factor VIII
             (hFVIII) of ≥ 0.6 Bethesda units (BU), as tested at screening at the central
             laboratory

          5. Participant is not currently receiving or has recently received (&lt; 30 days) immune
             tolerance induction (ITI) therapy

          6. Participant has a Karnofsky performance score of ≥ 60 at screening

          7. Participant is human immunodeficiency virus negative (HIV-); or HIV+ with stable
             disease and CD4+ count ≥ 200 cells/mm^3 at screening

          8. Participant is hepatitis C virus negative (HCV-) by antibody or polymerase chain
             reaction (PCR) testing; or HCV+ with chronic stable hepatitis disease. Positive
             serologies will be confirmed by PCR testing.

          9. Participant is willing and able to comply with the requirements of the protocol.

        Exclusion Criteria

          1. The participant requires emergency surgery

          2. Severe chronic liver dysfunction or disease (e.g., ≥ 5 × upper limit of normal [ULN]
             alanine aminotransferase [ALT], as confirmed by central laboratory at screening or a
             documented prothrombin time/international normalized ratio [PT/INR] &gt; 1.5)

          3. Clinically symptomatic renal disease (serum creatinine &gt; 2.0 mg/dL), as confirmed by
             central laboratory at screening

          4. Anti-porcine factor VIII (pFVIII) inhibitor &gt; 10 BU prior to surgery

          5. Platelet count &lt; 100,000/μL at screening

          6. Participant has another active coagulation disorder, other than hemophilia A, as per
             the medical history

          7. Planned use of α-interferon with or without ribavirin for HCV infected patients or
             planned use of a protease inhibitor for HIV infected patients. Patients currently
             taking any of these medications for ≥ 30 days are eligible

          8. Known hypersensitivity to recombinant porcine factor VIII (rpFVIII), or hamster or
             murine proteins

          9. Participant has an ongoing or recent (within 3 months of screening) thrombo-embolic
             disease, fibrinolysis or disseminated intravascular coagulation (DIC)

         10. Participant has been exposed to an IP within 30 days prior to enrollment or is
             scheduled to participate in another clinical study involving an investigational
             product (IP) or investigational device during the course of this study

         11. Participant is unable to tolerate quantity of blood to be drawn for protocol
             procedures

         12. Participant is a family member or employee of the Investigator.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-7284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Tsaritsa Yoanna - ISUL', EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHATEM 'N.I. Pirogov', EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve-Rosemont d/b/a CIUSSS de l'Est-de-l'Île-de-Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn AoeR</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Hämostaseologie, Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus - Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0372</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii-1-1Y7-1347</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI of Science &quot;Kirov Scientific and Research Institute of Hematology and Blood Transfusion of FMBA.</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bleeding Disorders Unit and Clinical Haematology Service at Charlotte Maxeke JHB Academic Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>6590</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Medical Faculty</name>
      <address>
        <city>Kocaeli</city>
        <zip>41300</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2016</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

